ConcertAI Announces Strategic Agreement with Bayer to Accelerate Clinical Development in Precision Oncology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI announced a multi-year agreement with Bayer to leverage ConcertAI's Translational360™ and AI SaaS solutions, which use artificial intelligence and machine learning (AI/ML)-derived insights to accelerate clinical development in precision oncology.
The agreement will fully leverage ConcertAI's newly launched Translational360™, an integrated research-grade longitudinal clinical molecular database that taps into the CancerLinQ network of de-identified cancer patient data from over 9 million records coming from all 50 states in the U.S.
Translational360™ combines clinical, genomic, transcriptomic, and whole-slide imaging (WSI) from comprehensive molecular testing for deep phenotypical and genomic insights. Transcriptomics is increasingly a foundation of biopharma translational sciences, allowing researchers to understand disease molecular mechanisms, basis of patient response, and inter-patient variability that's essential for developing new therapeutics. Too often, clinical trial results in early phases are ambiguous with idiosyncratic positive and negative responses. The integrated data solutions and advanced AI enable selection of programs with the highest likelihood of success and design trials informed by multi-modal, multi-genomic, and transcriptomic data and AI.
'This partnership furthers causal biological inferences where multi-modal and multi-molecular data can be integrated with AI/ML-based approaches across discovery, translation, and development, accelerating oncology pipelines, allowing our biopharma partners to deliver better medicines faster,' said Jeff Elton, Ph.D., CEO of ConcertAI. 'This partnership builds on a multi-year history of working together and is unique in offering both tissue and liquid biopsy molecular data, allowing insights into patterns of treatment response, acquisition of resistance, AI modeling of likely success and benefit, informing program priority and clinical study design.'
'As cancer rates continue to rise, we're committed to advancing next-generation solutions that can speed up drug discovery and clinical development, enabling us to bring precision oncology treatments to patients faster,' said Sai Jasti, Head of Data Science and AI for Pharma R&D at Bayer. 'By combining ConcertAI's powerful data solutions with Bayer's scientific and AI expertise, we aim to enhance the use of real-world data and cutting-edge AI to boost R&D productivity and ultimately deliver transformative precision therapies to those who need them.'
'More AI-designed new molecular entities are progressing faster in first-in-human trials which is a great milestone,' said Claudio D'Ambrosio, Ph.D., Chief Revenue Officer of ConcertAI. 'Our entire R&D process has been historically built on studying controlled cell lines and animal models that don't reflect the interspecies differences, the physiology, and the different biological barriers we have in humans. We are flipping this paradigm on its head. We need to start with human cancer genomes and phenotypes and 'reverse translate.' Unlike only a few years ago, we now have powerful human data.'
About ConcertAI:
ConcertAI is a leader in predictive and generative AI SaaS and multi-modal real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai ™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon® provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, empowering oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
AM Best Withdraws Credit Ratings of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company
OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has withdrawn the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings of 'a' (Excellent) of FCCI Commercial Insurance Company and FCCI Advantage Insurance Company as these companies no longer operate as insurance companies. At the time of the withdrawal, the outlooks of these Credit Ratings (ratings) were stable. Both companies are domiciled in Sarasota, FL. AM Best's procedure is for a final rating opinion to be produced in conjunction with a rating withdrawal. However, final ratings could not be determined on these companies due to the absence of insurance licenses and liabilities. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments. AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit Copyright © 2025 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.
Business Wire
7 minutes ago
- Business Wire
Ultra Cyclist Philipp Kaider Embarks on Race Across America with Support from Radiometer
CARLSBAD, Calif.--(BUSINESS WIRE)--On June 10, 2025, Austrian ultra-endurance athlete Philipp Kaider will begin his most ambitious challenge yet: the Race Across America (RAAM). Spanning nearly 5,000 kilometers from the Pacific to the Atlantic, RAAM is widely regarded as one of the toughest endurance races in the world—demanding continuous cycling across extreme terrain, weather conditions, and time zones. To help monitor his hydration and recovery throughout the event, Kaider's team will use the ABL90 FLEX PLUS blood gas analyzer to measure critical values such as electrolytes—ensuring he remains in peak condition across each stage of the race. Share This marks Kaider's first attempt at the iconic race, a feat that tests not just physical strength, but also mental focus and strategic precision. Supported by a mobile crew and detailed performance planning, Kaider is determined to cross the finish line with speed and resilience. 'RAAM isn't just a race—it's a life experience,' said Kaider. 'It's about pushing past what you thought was possible and discovering a new level of endurance. I've trained for years to reach this starting line.' RAAM represents the ultimate test of human endurance, and Philipp's story reflects the passion and perseverance we admire at Radiometer. To help monitor his hydration and recovery throughout the event, Kaider's team will use the ABL90 FLEX PLUS blood gas analyzer to measure critical values such as electrolytes—ensuring he remains in peak condition across each stage of the race. About Radiometer Whatever comes next, we make sure life comes first. Radiometer develops, manufactures, and markets solutions for blood sampling, blood gas analysis, transcutaneous monitoring, immunoassay testing, and related IT management systems. Today, Radiometer's products and solutions are used in hospitals, clinics, and laboratories in over 130 countries, providing information on critical parameters in acute care diagnostics. Through connected solutions, expert knowledge, and trusted partnerships, we help health care professionals make diagnostic decisions to improve patient care. To learn more, visit or contact Radiometer America at 1 (800) 736 0600. About RAAM RAAM, first held in 1982, differs from stage-based races by running non-stop from start to finish. Riders have no designated rest periods, making strategic decisions about sleep, nutrition, and pacing crucial for success.
Business Wire
7 minutes ago
- Business Wire
Monarch Launches to Empower Women's Health Physicians with a Bold New Model for Independent, Membership-Based Care
NEW YORK--(BUSINESS WIRE)-- Monarch has officially launched to transform the future of women's healthcare by enabling physicians to establish and operate independent, membership-based practices. Founded by physicians and industry veterans, Monarch's approach supports a sustainable alternative to traditional systems that limit time, access, and quality of care, ensuring doctors retain complete ownership, clinical decision-making authority, and professional autonomy. Addressing Crisis-Level Burnout and Patient Dissatisfaction After assembling its first physician cohort, Monarch launches amid growing urgency and demand for a better way to practice medicine. Recent reports show that nearly half of U.S. physicians report experiencing symptoms of burnout, which particularly impacts women's healthcare where complex care requires longer consultations that current reimbursement models fail to adequately support. Women across the country also face increasing delays, dismissals, misdiagnosis, and fragmented care. These disparities underscore the need for a better healthcare model. Monarch helps remove the friction and bureaucracy that drives burnout and prevents physicians from delivering the care their patients deserve. By providing comprehensive operational infrastructure, dedicated launch support, and robust practice management tools, Monarch enables physicians to spend significantly more time delivering thoughtful, preventive care that reflects the full complexity of women's health rather than being overwhelmed by administrative burdens. 'Monarch was built to address a fundamental failure in healthcare: The system is broken, and it's women who are too often overlooked, underserved, and left behind,' said Anna Lohrfink, Co-Founder and Chief Product Officer of Monarch. 'Our mission is simple: Empower great doctors to deliver the care women deserve—personal, proactive, and focused on helping them thrive in every stage of life.' Built for Physician Independence and Patient-Centered Care Monarch-affiliated physicians retain full ownership of their practices and complete clinical decision-making power. Monarch minimizes administrative burden—from staffing to billing, marketing, and technology integration—enabling physicians to maintain smaller patient panels, offer extended appointments, provide greater care continuity, and generate more predictable revenue through the membership model. 'Monarch makes it possible to practice medicine the way it was always meant to be practiced—rooted in deep relationships, centered on the full spectrum of health, and driven by clinical excellence,' said Dr. Suzanne Gilberg, Chief Clinical Officer, Monarch. 'We're not opting out of the healthcare system—we're building what it should have been all along, for both patients and physicians.' Proven Leadership and Vision Monarch's founding team combines deep expertise in healthcare delivery, digital health, and practice operations, supported by distinguished clinical advisors specializing in women's health, concierge medicine, and healthcare innovation. This helps ensure the platform remains grounded in the real needs of both patients and providers. "This is about giving physicians their professional identity back," added Lohrfink. "When doctors are free to build meaningful relationships with patients—without the noise of administrative red tape—healthcare finally does what it's meant to do: help people live healthier, fuller lives." About Monarch Monarch is the premier partner for women's health physicians who want to leave behind a high-volume, insurance-driven care and build independent practices that deliver exceptional, personalized care for women at every stage of life. Monarch provides the operational support, technology, and investment physicians need—without taking away ownership or clinical autonomy. With Monarch's proven model, physicians reduce patient volume, deliver proactive, personalized care, and build stronger relationships with their patients. Physicians interested in learning more about Monarch can visit and follow Monarch on LinkedIn.
